Rafarma Pharmaceuticals (RAFA) Stock Statistics & Valuation Metrics
Total Valuation
Rafarma Pharmaceuticals has a market cap or net worth of $1.45M. The enterprise value is $4.31T.
- Market Cap
- $1.45M
- Enterprise Value
- $4.31T
Share Statistics
Rafarma Pharmaceuticals has 87,767,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 87,767,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Rafarma Pharmaceuticals’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 3.80%.
- Return on Equity (ROE)
- 0.03
- Return on Assets (ROA)
- 0.03
- Return on Invested Capital (ROIC)
- 3.80%
- Return on Capital Employed (ROCE)
- 0.05
- Revenue Per Employee
- 13.11K
- Profits Per Employee
- 498.571
- Employee Count
- 700
- Asset Turnover
- 0.77
- Inventory Turnover
- 53.27
Valuation Ratios
The current PE Ratio of Rafarma Pharmaceuticals is 7.62. Rafarma Pharmaceuticals’s PEG ratio is 0.29.
- PE Ratio
- 7.62
- PS Ratio
- 0.17
- PB Ratio
- 0.15
- Price to FCF
- 36.61
- Price to Operating Cash Flow
- 34.95
- PEG Ratio
- 0.29
Income Statement
In the last 12 months, Rafarma Pharmaceuticals had revenue of 9.18M and earned 349.00K in profits. Earnings per share was 0.00.
- Revenue
- 9.18M
- Gross Profit
- 761.00K
- Operating Income
- 489.00K
- Pretax Income
- 427.00K
- Net Income
- 349.00K
- EBITDA
- 489.00K
- Earnings Per Share (EPS)
- 0.00
Cash Flow
In the last 12 months, operating cash flow was 43.00K and capital expenditures -2,000, giving a free cash flow of 41.00K billion.
- Operating Cash Flow
- 43.00K
- Free Cash Flow
- 41.00K
- Free Cash Flow per Share
- 0.00
Dividends & Yields
Rafarma Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.73%
- Earnings Yield
- 23.87%
Stock Price Statistics
- Beta
- 0.64
- 52-Week Price Change
- -54.05%
- 50-Day Moving Average
- 0.03
- 200-Day Moving Average
- 0.04
- Relative Strength Index (RSI)
- 47.34
- Average Volume (3m)
- 26.98K
Financial Position
Rafarma Pharmaceuticals as a current ratio of 1.13, with Debt / Equity ratio of 0.22%
- Current Ratio
- 1.13
- Quick Ratio
- 1.03
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- -0.07
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Rafarma Pharmaceuticals has paid 78.00K in taxes.
- Income Tax
- 78.00K
- Effective Tax Rate
- 0.18
Enterprise Valuation
Rafarma Pharmaceuticals EV to EBITDA ratio is 2.95, with an EV/FCF ratio of 35.71.
- EV to Sales
- 0.16
- EV to EBITDA
- 2.95
- EV to Free Cash Flow
- 35.71
- EV to Operating Cash Flow
- 34.08
Balance Sheet
Rafarma Pharmaceuticals has $60.00K in cash and marketable securities with $22.00K in debt, giving a net cash position of $38.00K billion.
- Cash & Marketable Securities
- $60.00K
- Total Debt
- $22.00K
- Net Cash
- $38.00K
- Net Cash Per Share
- $0.00
- Tangible Book Value Per Share
- $0.12
Margins
Gross margin is 8.54%, with operating margin of 5.50%, and net profit margin of 3.97%.
- Gross Margin
- 8.54%
- Operating Margin
- 5.50%
- Pretax Margin
- 4.86%
- Net Profit Margin
- 3.97%
- EBITDA Margin
- 5.50%
- EBIT Margin
- 5.50%
Analyst Forecast
The average price target for Rafarma Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
